Assertio (ASRT) Stock Price, News & Analysis

Company Overview

Assertio Therapeutics, Inc. (NASDAQ: ASRT) is a specialty pharmaceutical company focused on developing and commercializing treatments for patients with chronic and rare disorders. The company’s core areas of expertise include neurology, pain management and migraine prevention. With a portfolio of both marketed therapies and pipeline assets, Assertio seeks to address unmet medical needs through targeted drug delivery and strategic partnerships.

Assertio’s marketed products include Gralise, an extended-release formulation of gabapentin for post-herpetic neuralgia; Zipsor, a topical diclofenac epolamine gel designed for the treatment of acute pain; and Cambia, a diclofenac potassium powder for oral suspension indicated for acute migraine attacks. In addition, the company has advanced Qulipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, through regulatory approval for the preventive treatment of episodic migraine. These therapies reflect Assertio’s commitment to offering differentiated dosage forms and improved patient convenience.

Originally founded in 1995 as Depomed, the organization rebranded to Assertio Therapeutics in 2017 to underscore its sharpened focus on neurological and pain indications. Headquartered in Naperville, Illinois, the company operates across the United States and collaborates with global partners to extend the reach of its products. Assertio’s commercial strategy combines direct sales with licensing agreements, enabling access to a broader patient population while leveraging the marketing capabilities of international pharmaceutical firms.

Under the leadership of a seasoned executive team, including co-founder and Chief Executive Officer Ray Berger, Assertio continues to pursue growth through both in-license opportunities and internal research programs. The company’s research and development efforts aim to expand its pipeline in migraine prevention and other neurological conditions, with an emphasis on innovation in drug delivery systems. Assertio’s strategic initiatives are supported by a governance framework that prioritizes clinical excellence and value creation for patients and stakeholders alike.

Key Stats

• Today's Range: $0.69 to $0.72
• 50-Day Range: $0.61 to $0.71
• 52-Week Range: $0.51 to $1.80
• Volume: 94,459 shs
• Average Volume: 538,161 shs
• Market Capitalization: $66.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.75
• Consensus Rating: Buy

Assertio Stock Analysis - MarketRank™

Assertio scored higher than 36% of companies evaluated by MarketBeat, and ranked 729th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Assertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Assertio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Assertio are expected to grow in the coming year, from ($0.15) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Assertio is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Assertio is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Assertio has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.37% of the float of Assertio has been sold short.

Short Interest Ratio / Days to Cover

Assertio has a short interest ratio ("days to cover") of 20.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Assertio has recently increased by 1.56%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assertio does not currently pay a dividend.

Dividend Growth

Assertio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.37% of the float of Assertio has been sold short.

Short Interest Ratio / Days to Cover

Assertio has a short interest ratio ("days to cover") of 20.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Assertio has recently increased by 1.56%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: N/A

News Sentiment

Assertio has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Assertio this week, compared to 1 article on an average week.

Search Interest

4 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Assertio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.00% of the stock of Assertio is held by insiders.

Percentage Held by Institutions

48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ASRT Stock Analysis - Frequently Asked Questions

How have ASRT shares performed this year?

Assertio's stock was trading at $0.8711 at the beginning of the year. Since then, ASRT stock has decreased by 20.7% and is now trading at $0.6910.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.08. The firm had revenue of $26.49 million for the quarter, compared to analyst estimates of $27.52 million. Assertio had a negative net margin of 25.72% and a negative trailing twelve-month return on equity of 24.87%.
Read the conference call transcript.

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASRT
• CIK: 1808665
• Web: www.assertiotx.com
• Phone: (224) 419-7106
• Fax: 510-744-8001
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Assertio: $2.75
• High Price Target: $3.50
• Low Price Target: $1.75
• Potential Upside/Downside: +298.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.58 million
• Net Margins: -25.72%
• Pretax Margin: -25.59%
• Return on Equity: -24.87%
• Return on Assets: -10.87%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 1.66
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $124.96 million
• Price / Sales: 0.53
• Cash Flow: $0.05 per share
• Price / Cash Flow: 14.47
• Book Value: $1.27 per share
• Price / Book: 0.54

Miscellaneous

• Outstanding Shares: 95,780,000
• Free Float: 91,950,000
• Market Cap: $66.18 million
• Optionable: Optionable
• Beta: 0.29